Research output per year
Research output per year
-
Author Correction: Virus-induced senescence is a driver and therapeutic target in COVID-19
Lee, S., Yu, Y., Trimpert, J., Benthani, F., Mairhofer, M., Richter-Pechanska, P., Wyler, E., Belenki, D., Kaltenbrunner, S., Pammer, M., Kausche, L., Firsching, T. C., Dietert, K., Schotsaert, M., Martínez-Romero, C., Singh, G., Kunz, S., Niemeyer, D., Ghanem, R. & Salzer, H. J. F. & 28 others, , Feb 2025, In: Nature. 638, 8052, p. E46Research output: Contribution to journal › Article › peer-review
-
Chronic Stress Stimulates Protumor Macrophage Polarization to Propel Lung Cancer Progression
Liu, C., Du, H., Yu, G., Qi, J., Dong, H., Hu, R., Wang, F., Cui, B., Chen, W., Zhang, Q., Li, C., Gao, R., Schmitt, C. A., Deng, J., Yu, Y. & Du, J., 09 Apr 2025, (E-pub ahead of print) In: Cancer research.Research output: Contribution to journal › Article
-
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial
Rinnerthaler, G., Egle, D., Bartsch, R., Schmitt, C. A., Petzer, A., Balic, M., Petru, E., Denison, U., Singer, C. F., Bjelic-Radisic, V., Gampenrieder, S. P., Knauer, M., Sotlar, K., Brunner, C., Posch, F., Hlauschek, D., Sölkner, L., Bago-Horvath, Z., Filipits, M. & Gili, M. & 10 others, , Jan 2025, In: Nature Cancer. 6, 1, p. 41-50 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Persistence and/or Senescence: Not So Lasting at Last?
Schmitt, C., 02 Jan 2025, In: Cancer Research. 85, 1, p. 7-9 3 p.Research output: Contribution to journal › Article › peer-review
-
Anti-angiogenesis and anti-immunosuppression gene therapy through targeting COUP-TFII in an in situ glioblastoma mouse model
Wang, F., Zhang, S., Sun, F., Chen, W., Liu, C., Schmitt, C. & et al., Aug 2024, In: Nature Cancer. 31, 8, p. 1135-1150 16 p.Research output: Contribution to journal › Article › peer-review
-
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia (ARGX-113-2402)
Schmitt, C. (PI), Krivic, D. (Researcher), Lichtenauer, N. (Researcher), Kühr, T. (Researcher), Schneeweiß, B. (Researcher), Piringer, G. (Researcher), Popp, H. D. (Researcher), Krenosz, K. J. (Researcher), Ghanem, R. (Researcher), Solomianyi, O. (Researcher), Schwarz, H. K. (Researcher), Kovacsova, J. (Researcher), Kausche, L. E. (Researcher), Stegemann, M. (Researcher), Klein, K. (Researcher) & Trathnigg, N. (Researcher)
04.06.2025 → 31.05.2029
Project: Clinical studies › Clinical Study (Industry project)
-
Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti- CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma (MorningLyte)
Schmitt, C. (PI), Krivic, D. (Researcher), Lichtenauer, N. (Researcher), Kühr, T. (Researcher), Schneeweiß, B. (Researcher), Piringer, G. (Researcher), Popp, H. D. (Researcher), Krenosz, K. J. (Researcher), Ghanem, R. (Researcher), Solomianyi, O. (Researcher), Schwarz, H. K. (Researcher), Kovacsova, J. (Researcher), Kausche, L. E. (Researcher), Stegemann, M. (Researcher), Klein, K. (Researcher) & Trathnigg, N. (Researcher)
02.06.2025 → 31.05.2029
Project: Clinical studies › Clinical Study (Industry project)
-
CANDOR : Cancer Odor
Narzt, W. (Researcher), Schmitt, C. (Researcher), Ghanem, R. (Researcher) & Langer, R. (Researcher)
01.02.2025 → 31.07.2025
Project: Clinical studies › Clinical Study (Funded research)
-
AGMT Metastasic Colorectal Cancer Registry (mCRC) Third Line and Beyond (mCRC Registry)
Krivic, D. (Researcher), Piringer, G. (PI), Lichtenauer, N. (Researcher), Schmitt, C. (Researcher), Kühr, T. (Researcher), Schneeweiß, B. (Researcher), Popp, H. D. (Researcher), Krenosz, K. J. (Researcher), Ghanem, R. (Researcher), Solomianyi, O. (Researcher), Schwarz, H. K. (Researcher), Kovacsova, J. (Researcher), Kausche, L. E. (Researcher), Stegemann, M. (Researcher), Klein, K. (Researcher) & Trathnigg, N. (Researcher)
20.12.2024 → 31.12.2029
Project: Clinical studies › Clinical Study (Industry project)
-
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery (MK-2870-012)
Krivic, D. (Researcher), Preuß, C. I. (PI), Schwarz, H. K. (Researcher), Schmitt, C. (Researcher), Kühr, T. (Researcher), Schneeweiß, B. (Researcher), Piringer, G. (Researcher), Popp, H. D. (Researcher), Krenosz, K. J. (Researcher), Ghanem, R. (Researcher), Solomianyi, O. (Researcher), Kovacsova, J. (Researcher), Kausche, L. E. (Researcher), Stegemann, M. (Researcher), Klein, K. (Researcher), Trathnigg, N. (Researcher) & Lichtenauer, N. (Researcher)
18.12.2024 → 31.12.2029
Project: Clinical studies › Clinical Study (Industry project)
Activities
-
T-Zell-Lymphome
Schmitt, C. (Speaker)
25 Nov 2023Activity: Talk or presentation › Invited talk › science-to-science
-
Apoptosis-competent anticancer treatment failure
Schmitt, C. (Speaker)
15 Nov 2023Activity: Talk or presentation › Invited talk › science-to-science
-
Hochmaligne NHL – neue Therapien inklusive bispezifische Antikörper
Schmitt, C. (Speaker)
11 Nov 2023Activity: Talk or presentation › Invited talk › science-to-science
-
Senolysis in cancer: from first preclinical evidence to patient benefit
Schmitt, C. (Speaker)
07 Nov 2023Activity: Talk or presentation › Invited talk › science-to-science
-
Clinical vignettes of pre- and post-senescence in cancer
Schmitt, C. (Speaker)
12 Oct 2023Activity: Talk or presentation › Invited talk › science-to-science